Please assess the completion status of the following clinical trial:

Trial Title: Apixaban For Thromboprophylaxis In Patients With Acute Spinal Cord Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients (≥18 years old) with acute spinal cord injury (SCI) presenting to the hospital within 1 week of SCI and is at least 36 h after the injury~* Traumatic SCI~* SCI with or without other injuries~Exclusion Criteria:~* Already on therapeutic oral anticoagulation prior to enrollment~* Active bleeding, intracranial or perispinal hematoma, or acquired or congenital bleeding disorder~* Pregnancy or breast feeding~* Severe renal failure (creatinine clearance ≤30 ml/min)~* Liver cirrhosis~* Severe thrombocytopenia (platelets \<50)~* Attending physician believes that the patient is not suitable for the study (for example, psychiatric disorder; history of non-compliance)~* Geographic inaccessibility: planned transfer to other site where follow-up not possible~* Failure to obtain written consent~* Previous hypersensitivity reaction to study drugs~* Patients with expected short hospital admission (≤7 days) due to minor injury

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Apixaban (Type: EXPERIMENTAL): Apixaban 2.5 mg orally twice daily
- Low Molecular Weight Heparin (Type: ACTIVE_COMPARATOR): Either enoxaparin 40 mg or dalteparin 5000 units subcutaneously once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).